UPDATE: Goldman Sachs Starts Iovanace Biotherapeutics (IOVA) at Buy

April 16, 2021 3:08 AM EDT
Get Alerts IOVA Hot Sheet
Price: $28.52 -0.31%

Rating Summary:
    11 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 38 | Down: 18 | New: 7
Trade Now! 
Join SI Premium – FREE
(Updated - April 16, 2021 4:13 AM EDT)

Goldman Sachs analyst Madhu Kumar initiates coverage on Iovanace Biotherapeutics (NASDAQ: IOVA) with a Buy rating and a price target of $97.00.

The analyst comments "Our 12-month price target of $97 implies 223% upside potential. Considering the unmet need for post-PD-(L)1 solid cancer therapies, Iovance’s tumor-infiltrating lymphocyte (TIL) platform could be the next major I-O drug class, with efficacy in post-PD-1 metastatic melanoma (MM), post-chemo cervical cancer (CC), head and neck squamous cell cancer (HNSCC), and non-small cell lung cancer (NSCLC)."

For an analyst ratings summary and ratings history on Iovanace Biotherapeutics click here. For more ratings news on Iovanace Biotherapeutics click here.

Shares of Iovanace Biotherapeutics closed at $30.43 yesterday.


You May Also Be Interested In





Related Categories

Analyst Comments, New Coverage

Related Entities

Goldman Sachs